PPARD

Peroxisome proliferator-activated receptor delta · Q03181 · PPARD on Sugi Atlas →

359,387 patent compounds predicted against PPARD, 206,401 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tesaglitazar (SCHEMBL16594)	0.61	10/20
Stearic Acid (SCHEMBL659)	1.00	7/20
Decanoic Acid (SCHEMBL2682)	1.00	7/20
Octanoic Acid (SCHEMBL3933)	1.00	7/20
Dodecanoate (SCHEMBL5895)	1.00	7/20
Heptadecanoic Acid (SCHEMBL5941)	1.00	7/20
Palmitic Acid (SCHEMBL6177)	1.00	7/20
Pentadecanoic Acid (SCHEMBL6311)	1.00	7/20
Myristic Acid (SCHEMBL6374)	1.00	7/20
Arachidic Acid (SCHEMBL6539)	1.00	7/20
Behenic Acid (SCHEMBL6579)	1.00	7/20
Undecanoate (SCHEMBL9266)	1.00	7/20
Nonanoate (SCHEMBL21966)	1.00	7/20
Tridecanoate (SCHEMBL22778)	1.00	7/20
Decanoic Acid (SCHEMBL38577)	1.00	7/20
N-Octacosanoic Acid (SCHEMBL49866)	1.00	7/20
Stearic Acid (SCHEMBL936)	0.94	7/20
Stearic Acid (SCHEMBL2372)	0.94	7/20
Stearic Acid (SCHEMBL4102)	0.94	7/20
Stearic Acid (SCHEMBL4924)	0.94	7/20

Clinical trials — most relevant to PPARD by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients	PHASE4	COMPLETED
The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome	PHASE4	COMPLETED
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects	PHASE4	COMPLETED
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone	PHASE4	COMPLETED
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Safety Study of Pioglitazone Compared To Glyburide on Liver Function	PHASE4	COMPLETED
How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine?	PHASE4	UNKNOWN
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.	PHASE4	COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus	PHASE3	COMPLETED
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	PHASE3	COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Rosiglitazone to Reverse Metabolic Defects in Diabetes	PHASE2	COMPLETED
Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes	PHASE2	COMPLETED
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease	PHASE2	COMPLETED
Pioglitazone Therapy Targeting Fatigue in Breast Cancer	PHASE2	RECRUITING
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)	PHASE1/PHASE2	COMPLETED
Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus	PHASE1	WITHDRAWN
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients	nan	COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
Pioglitazone Attenuates Dysmetabolism in Peritoneal Dialysis (PD) Patients	nan	COMPLETED
Role of FGF21 in Breast Cancer	nan	NOT_YET_RECRUITING
In and ex Vivo Mitochondrial Function of the Heart	nan	COMPLETED
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome	nan	COMPLETED
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function	nan	UNKNOWN
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy	nan	COMPLETED
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients	nan	COMPLETED
Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPARD binder may also engage these)

Protein	Name	Similarity
Q0ZAQ8	—	1.000	Q0ZAQ8 →
P35396	—	1.000	P35396 →
O35507	—	0.998	O35507 →
Q95N78	—	0.998	Q95N78 →
Q8HYL6	—	0.998	Q8HYL6 →
P37230	—	0.998	P37230 →
P23204	—	0.997	P23204 →
PPARA	Peroxisome proliferator-activated receptor alpha	0.996	landscape →
P37232	—	0.995	P37232 →
Q9XTJ4	—	0.995	Q9XTJ4 →
P37234	—	0.995	P37234 →
P57797	—	0.995	P57797 →
P37233	—	0.995	P37233 →
O18971	—	0.994	O18971 →
P28700	—	0.994	P28700 →
P51448	—	0.994	P51448 →
F1QLY4	—	0.994	F1QLY4 →
O01930	—	0.994	O01930 →
O17898	—	0.994	O17898 →
O62807	—	0.994	O62807 →
ESRRB	Steroid hormone receptor ERR2	0.994	landscape →
Q64249	—	0.994	Q64249 →
O45436	—	0.994	O45436 →
O18924	—	0.993	O18924 →
Q8ITW8	—	0.993	Q8ITW8 →
Q90415	—	0.993	Q90415 →
P37238	—	0.993	P37238 →
RORA	Nuclear receptor ROR-alpha	0.993	landscape →
P50569	—	0.993	P50569 →
P51128	—	0.993	P51128 →